Generic Name and Formulations:
Cefazolin (as sodium) 500mg/vial, 1g/vial; pwd for IM or IV inj or IV infusion after reconstitution and dilution; sodium content 48mg/g cefazolin.
Various generic manufacturers
Indications for Cefazolin:
Susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, bone and joint, endocarditis. Surgical prophylaxis.
Pneumococcal pneumonia: 500mg every 12 hours. Mild infections: 250–500mg every 8 hours; moderate to severe infections: 500mg–1g every 6–8 hours. Severe, life-threatening infections (eg, endocarditis, septicemia): 1–1.5g every 6 hours; max 12g/day. UTIs: 1g every 12 hours. Prophylaxis: see literature. Renal impairment (give initial loading dose): (CrCl 35–54mL/min): reduce dosing frequency to at least 8 hour intervals; (CrCl 11–34mL/min): reduce dose by 50%, give every 12 hours; (CrCl <10mL/min): reduce dose by 50%, give every 18–24 hours. Peritoneal dialysis: see literature.
<1 month: not recommended. ≥1 month: Mild to moderately severe infections: 25–50mg/kg per day in 3–4 divided doses. Severe infections: max 100mg/kg per day. Renal impairment (give initial loading dose): (CrCl 40–70mL/min): reduce dose by 40%; give every 12 hours; (CrCl 20–40mL/min): reduce dose by 75%, give every 12 hours; (CrCl 5–20mL/min): reduce dose by 90%, give every 24 hours.
Penicillin or other allergy. Renal impairment: reduce dose. GI disease (esp. colitis). Monitor PT in patients at risk (eg, renal or hepatic impairment, poor nutritional state, long term use, or anticoagulant therapy). Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) Clinitest, Benedict's, or Fehling's soln.
GI upset, anaphylaxis, rash, pruritus, local reactions, blood dyscrasias, elevated liver enzymes.
Formerly known under the brand names Ancef, Kefzol.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Stroke in Women: Risk, Prevention, and Treatment
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline